Pharmaceuticals, Biotechnology and Life Sciences
Novartis’ Sandoz, received on Tuesday from the European Commission (EC) the marketing authorization for biosimilar Ziextenzo (pegfilgrastim), which is indicated to reduce the…
After the Oasmia Pharmaceutical’s pivotal study OAS 07OVA conducted on ovarian cancer patients with disease relapse, showed that the risks…
Denali Therapeutics, a neurodegenerative diseases specialist, on Tuesday brought to public positive results from its Phase 1 healthy volunteer study of DNL747, a brain penetrant small molecule inhibitor of receptor-interacting serine/threonine-protein kinase 1 (RIPK1),
Basilea Pharmaceutica will presenting its new preclinical data on its clinical stage anticancer drug candidate BAL101553 at the 30 EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland.
AstraZeneca and Merck’s Phase III SOLO-1 trial of Lynparza (olaparib) tablets, for women with BRCA-mutated (BRCAm) advanced ovarian cancer treated…
The US Food and Drug Administration approved Merck’s Keytruda (pembrolizumab) for patients with recurrent or metastatic cervical cancer with disease…
A clinical stage biopharmaceutical company, 4D pharma, pioneering the development of Live Biotherapeutic Products, has made a deal with a subsidiary of…
Boehringer Ingelheim’s study showed that dose adjustment with Gilotrif helped improve patient tolerability while maintaining treatment efficacy and reduced the frequency…
AstraZeneca and MedImmune, its global biologics research and development arm, on Friday reported positive overall survival (OS) results for the…
The Medicines and Healthcare products Regulatory Agency (MHRA) has cleared 4D pharma’s Clinical Trial Application for MRx0518, a live biotherapeutic…